EastGate Biotech Corp. has announced that it has commenced scale-up activities for its proprietary intraoral insulin tablet. The company is now equipped with all necessary pharmaceutical machinery required for the development and finalization of the scale-up manufacturing process.

The developed manufacturing process along with analytical methods will be transferred to a selected contract GMP manufacturing facility wherein a clinical batch will be produced. The transferred technology and preparation processes will also fulfill production requirements for commercial batches in the future after regulatory approval is obtained. The delivery and implementation of the current equipment was facilitated by Proactive Supply Chain Solutions.

The company announced it is successfully advancing in a formulation development of a 25 IU intraoral insulin tablet, designed to manage mealtime glucose levels. The intraoral insulin tablet dissolves under the tongue and delivers insulin to the bloodstream. The tablet is proposed for the treatment of Type 2 diabetes mellitus and pre-diabetic condition.

The tablet can also be used as an add-on therapy in combination treatment with other oral anti-diabetic drugs.